What's Happening?
Intellia Therapeutics, a biopharmaceutical company, has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for its CRISPR-based gene editing therapy, lonvoguran ziclumeran (lonvo-z),
aimed at treating hereditary angioedema (HAE). This one-time treatment is designed to inactivate the kallikrein B1 (KLKB1) gene, thereby reducing levels of kallikrein and bradykinin, which are associated with the condition. The therapy has shown promising results in the Phase 3 HAELO clinical trial, meeting primary and secondary endpoints by preventing HAE attacks and reducing the need for ongoing therapy. Intellia plans to complete the BLA submission in the second half of 2026, with a potential commercial launch in the first half of 2027, pending FDA approval.
Why It's Important?
The development of lonvo-z represents a significant advancement in the treatment of hereditary angioedema, a rare genetic disorder characterized by severe and unpredictable inflammatory attacks. Current treatments often require lifelong administration and can still result in breakthrough attacks. If approved, lonvo-z would be the first in vivo CRISPR-based gene editing therapy, potentially transforming the standard of care by offering a one-time treatment option. This could significantly reduce the burden on patients, who currently rely on frequent and ongoing therapies. The approval and success of this treatment could also pave the way for further CRISPR-based therapies, highlighting the potential of gene editing technologies in addressing genetic disorders.
What's Next?
Intellia Therapeutics is expected to complete its BLA submission by the second half of 2026. The FDA will then review the application, potentially granting a priority review which could expedite the process. If approved, Intellia plans to launch the treatment commercially in the first half of 2027. The company will continue to engage with the FDA to facilitate the review process, leveraging the Regenerative Medicine Advanced Therapy (RMAT) designation to potentially expedite approval. The outcome of this submission could influence future regulatory approaches to CRISPR-based therapies and impact the broader field of genetic medicine.
